Oxford Nanopore Technologies plc (ONTTF)
| Market Cap | 1.69B -0.7% |
| Revenue (ttm) | 301.35M +22.2% |
| Net Income | -195.42M |
| EPS | -0.20 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.800 |
| Previous Close | 1.770 |
| Day's Range | 1.800 - 1.800 |
| 52-Week Range | 1.400 - 3.340 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About ONTTF
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a ... [Read more]
Financial Performance
In 2025, ONTTF's revenue was 223.90 million, an increase of 22.22% compared to the previous year's 183.20 million. Losses were -145.20 million, -0.68% less than in 2024.
Financial numbers in GBP Financial StatementsNews
Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan
OXFORD, England & TOKYO--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations...
Oxford Nanopore Technologies Transcript: Barclays 28th Annual Global Healthcare Conference
Revenue growth is strong in clinical and applied industrial markets, with rapid adoption in rare disease, infectious disease, and oncology. Technology differentiation, strategic partnerships, and biopharma applications are driving expansion, while financial targets have been adjusted to reflect market and execution challenges.
ViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore Sequencing
OXFORD, England & VIENNA--(BUSINESS WIRE)-- #Nanopore--ViruSure, an Asahi Kasei company and global leader in pathogen safety testing for biopharmaceuticals, today announced the launch of the world's f...
Oxford Nanopore Technologies Earnings Call Transcript: H2 2025
FY 2025 saw 24% revenue growth, margin expansion, and improved EBITDA loss, driven by strong applied market performance and disciplined cost control. FY 2026 guidance targets 21–25% revenue growth, 62% gross margin, and continued operational leverage, with breakeven EBITDA expected in 2027.
Oxford Nanopore Technologies Annual report: H2 2025
Oxford Nanopore Technologies has published its H2 2025 annual report on March 2, 2026.
Oxford Nanopore Technologies Slides: H2 2025
Oxford Nanopore Technologies has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 2, 2026.
Oxford Nanopore Technologies Annual report: H2 2025
Oxford Nanopore Technologies has published its H2 2025 annual report on March 2, 2026.
Oxford Nanopore Technologies Transcript: Fireside Chat
Revenue and cash performance exceeded expectations, driven by strong growth in clinical and biopharma segments, a shift to a CapEx model, and ongoing innovation. Despite regional and execution challenges, the outlook remains positive with ambitious financial targets and new product launches expected to drive future growth.
Oxford Nanopore Technologies Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong revenue growth and market expansion were driven by differentiated sequencing technology, with clinical and biopharma segments showing rapid gains. Strategic innovation, new business models, and leadership transition position the company for continued growth and profitability.
Oxford Nanopore Technologies Slides: 44th Annual J.P. Morgan Healthcare Conference
Oxford Nanopore Technologies has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
Oxford Nanopore Technologies Earnings release: H2 2025
Oxford Nanopore Technologies released its H2 2025 earnings on January 12, 2026, summarizing the period's financial results.
Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies today announces that the GridION™ Dx is now both CE and UKCA marked, making it the company's first IVD device registered in t...
Oxford Nanopore Technologies Transcript: Piper Sandler 37th Annual Healthcare Conference
Leadership transition is underway with a focus on biopharma and clinical growth, targeting EBITDA break-even by 2027. Technology differentiation and strong execution have driven top-end revenue guidance, with new pricing models and partnerships supporting margin and market expansion. Biopharma QC and clinical segments are key growth drivers.
Oxford Nanopore Technologies Transcript: Citi Annual Global Healthcare Conference 2025
Upgraded 2025 guidance reflects strong growth in the Americas and clinical/biopharma sectors, with major contracts like UK Biobank set to drive 2026 revenue. Pricing and business model changes have improved margins and cash flow, while operational focus shifts to high-value segments and leadership transitions support future scalability.
Oxford Nanopore Announces PromethION Plus Flow Cell and Human Genetics Updates at ASHG 2025
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--At the American Society of Human Genetics (ASHG) 2025 industry session on 16th October, Oxford Nanopore Technologies will share its latest developments in...
Oxford Nanopore Technologies Earnings Call Transcript: H1 2025
Revenue grew 28% constant currency in H1 2025, with strong gains across all segments and regions. Gross margin reached 58.2% (61% excluding a one-off charge), and adjusted EBITDA loss improved 22% year-on-year. Guidance for 2025 is reaffirmed, with a focus on high-priority applied and clinical markets.
Oxford Nanopore Technologies Earnings release: H1 2025
Oxford Nanopore Technologies released its H1 2025 earnings on September 2, 2025, summarizing the period's financial results.
Oxford Nanopore Technologies Slides: H1 2025
Oxford Nanopore Technologies has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 2, 2025.
ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology
OXFORD, England & VIENNA, Austria--(BUSINESS WIRE)-- #Lifesciences--ViruSure, a global leader in pathogen safety testing for biopharmaceuticals, and Oxford Nanopore Technologies (“Oxford Nanopore”) (L...
Oxford Nanopore Technologies Earnings release: H1 2025
Oxford Nanopore Technologies released its H1 2025 earnings on July 21, 2025, summarizing the period's financial results.
Breakthrough algorithm enables partially phased, near telomere-to-telomere assembly using standard Oxford Nanopore Simplex reads
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--A new paper, released this week on bioRxiv, introduces hifiasm-ONT, a breakthrough genome assembly algorithm that enables partially phased, near telomere-...
Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies today announced the expansion of its Compatible Products Programme (CPP), welcoming a new cohort of leading partners whose pr...
Oxford Nanopore Technologies Earnings Call Transcript: H2 2024
FY 2024 revenue grew 23% underlying to £183.2m, with strong H2 momentum and margin improvement. 2025 guidance is 20%-23% growth, factoring in US and China headwinds, with continued focus on applied, clinical, and biopharma markets and operational efficiency.
Oxford Nanopore Technologies Annual report: H2 2024
Oxford Nanopore Technologies has published its H2 2024 annual report on March 4, 2025.
Oxford Nanopore Technologies Earnings release: H2 2024
Oxford Nanopore Technologies released its H2 2024 earnings on March 4, 2025, summarizing the period's financial results.